Person: Hollister-Lock, Jennifer
Loading...
Email Address
AA Acceptance Date
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
Hollister-Lock
First Name
Jennifer
Name
Hollister-Lock, Jennifer
Search Results
Now showing 1 - 1 of 1
Publication Genome-Scale in Vivo CRISPR Screen Identifies RNLS as a Target for Beta Cell Protection in Type 1 Diabetes(Springer Science and Business Media LLC, 2020-07-27) Cai, Erica P.; Ishikawa, Yuki; Zhang, Wei; de Carvalho Leite, Nayara; Li, Jian; Hou, Shurong; Kiaf, Badr; Hollister-Lock, Jennifer; Yilmaz, Nese Kurt; Schiffer, Celia A.; Melton, Douglas; Kissler, Stephan; Yi, PengType 1 diabetes (T1D) is caused by the autoimmune destruction of pancreatic beta cells. Pluripotent stem cells can now be differentiated into beta cells, raising the prospect of a cell replacement therapy for T1D. However, autoimmunity would rapidly destroy newly transplanted beta cells. Using a genome-scale CRISPR screen in a mouse model for T1D, here we show that deleting RNLS, a GWAS candidate gene for T1D, made beta cells resistant to autoimmune killing. Structure-based modeling identified the FDA-approved drug pargyline as a potential RNLS inhibitor. Oral pargyline treatment protected transplanted beta cells in diabetic mice, leading to disease reversal. Further, pargyline could prevent or delay diabetes onset in several mouse models for T1D. Our results identify RNLS as a modifier of beta cell vulnerability and as a potential therapeutic target to avert beta cell loss in T1D.